XML 19 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Revenue from Contracts with Customers
 3 Months Ended
Jul. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Services Revenue
The following tables represents disaggregated revenue for the three months ended July 31, 2022 and 2021:
Three Months Ended
July 31,
 20222021
Pharmacology services$12,756 $10,703 
Other TOS revenue948 526 
Personalized oncology services41 24 
Total oncology services revenue$13,745 $11,253 
Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and SaaS provided via our Lumin Bioinformatics software ("Lumin").

Contract Balances
Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period.